The trial was conducted at 23 CF Foundation accredited care centers in the United States between December 15, 2000, and May 2, 2002, and was coordinated by the CF Therapeutics Development Network Coordinating Center in Seattle, Wash. The institutional review board at each center approved the study and each participant or their parent/guardian voluntarily consented to participate. Eligibility criteria included a documented diagnosis of CF; age 6 years or older; weight of 25 kg or more; chronic infection with P aeruginosa, defined by a positive respiratory tract culture 1 year or more before screening and at screening; and a forced expiratory volume in 1 second (FEV1) of 30% or more of predicted. 12 Exclusion criteria were Burkholderia cepacia complex isolated from the respiratory tract at screening or within 2 years of screening; nontuberculous mycobacteria within 2 years of screening or acid-fast bacillus smear positive at screening; history of biliary cirrhosis or portal hypertension, splenomegaly on examination, or liver function results (ie, aspartate serum transferase, alanine transferase, 7-glutamyltransferase phosphate) of 2 or more times the upper limit of normal; use of intravenous 1750 JAMA, October 1, 2003-Vol 290, No. 13 antibiotics, quinolones, or other oral antibiotics within 14 days of screening; use of systemic corticosteroids (>20 mg of prednisone daily) within 30 days of screening; or initiation of tobramycin solution for inhalation, 13 recombinant human dornase alfa inhalation solution, 1314 or high-dose ibuprofen 15 within 60 days of screening. Long-term use of these medications was permissible.
Randomization and Blinding
Approximately equal allocation to azithromycin and placebo groups was planned to achieve reasonable balance within categories of disease severity (>60% or <60% of the predicted value of FEV 1 ) and weight (>40 kg or <40 kg) and within each study site. Because of the large number of sites and the relatively small number of participants at each site, an allocation strategy used an algorithm that recalculated the proportion of participants at each site with each set of baseline clinical characteristics, before each randomization assignment. 16 Randomization assignments and a series of blinded drug kit numbers were generated by the CF Therapeutics Development Network Coordinating Center. Kits were distributed to the centers and a centralized secure randomization system at the coordinating center was used to assign drug kit numbers to patient identification numbers at each site. All study personnel and participants were blinded to treatment assignment. The randomization codes for each participant were revealed to the researchers once recruitment, data collection, and data analyses were completed.
Treatment Regimen
Azithromycin was supplied as 250-mg tablets and the placebo was identically packaged. Participants who weighed less than 40 kg were instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday) and participants who weighed 40 kg or more were instructed to take 2 tablets on the same 3 days per week. The study drug was discontinued if a participant had an allergic reaction; a life-threatening adverse event, not including hospitalization for a pulmo- 
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Blood samples to monitor hematology, liver function, and creatinine were obtained at screening, day 28, and day 168. The Cystic Fibrosis Quality of Life Questionnaire was administered to all English-speaking participants and parents/guardians on days 0 and 168. [18] [19] [20] Audiology testing was performed on participants at 11 centers on days 0 and 168. Hearing loss was defined as at least 10 dB increase in auditory threshold at 1 or more of the following frequencies: 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz.
Primary and Secondary Outcomes
The primary outcomes of the study were to determine if azithromycin was associated with a change in FEV 1 from day 0 to completion of therapy (day 168) and whether it was safe, as determined by adverse events including selfreported symptoms, physical findings, laboratory tests, audiology, and microbiology. Secondary outcomes inan Medical Association. All rights reserved. 12 estimate the change from baseline to day study, 185 (74%) were randomized: 87 A standard microbiologic evaluation 168 for each participant. This approach to the azithromycin group and 98 to the of sputum and throat cultures for po-maximizes the use of repeated FEV1 mea-placebo group (FIGURE 1). Four particitential pathogens was performed by the surements obtained throughout the pants in the azithromycin group and 6 Therapeutics Development Network Mi-study from each participant. For each in the placebo group were lost to followcrobiology Core Laboratory. 22 Acid fast participant, a piecewise linear regres-up. All but 1 participant in the placebo bacillus smear and culture for nontuber-sion vs time (actual days of day 0,28,84, group, who was lost to follow-up beculous mycobacteria were performed on and 168 visits) was fit to his/her FEV1 fore the day 28 visit, were included in the sputum specimens only. 23 data by using day 28 as the change point efficacy analysis. The median number of Levels of IL-8 and neutrophil elas-at which a maximum initial response participants randomized per site was 8 tase activity were determined by the would be observed. This regression (range, 3-17) at each of the 23 study sites. Therapeutics Development Network In-model was used to estimate the 168-The baseline characteristics and randomflammatory Markers Core Laboratory day change for each participant. The ization strata were similar between treatby using an enzyme immunoassay mean 168-day change across particiment groups (TABLE 1) . Comparable (R&D Systems, Minneapolis, Minn) pants using these derived estimates was proportions of participants in each group and a kinetic spectrophotometric as-then compared between treatment used long-term concomitant medicasay (Sigma Chemicals, St Louis, Mo), groups by using a.05 level 2-sided t test.
tions at baseline; recombinant human respectively.
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If a participant had insufficient dornase alfa inhalation solution and todata to compute the change using this bramycin solution for inhalation were Sample Size Considerations approach (eg, were lost to follow-up), used by 75% and 61% of participants in We hypothesized that the mean (SD) de-his/her day 0 FEV1 measurement was the azithromycin group and 67% and crease in FEV1 in the placebo group subtracted from the last available mea-57% of participants in the placebo group, would be 0.05 (0.25) L and the mean surement to estimate the change from respectively. Compliance was moni-(SD) increase in the azithromycin group baseline included in the primary analy-tored by the number of pills dispensed would be 0.11 (0.28) Lafter 168 days of sis. The relative change in FEV1% pre-and returned, and was similar in both treatment. With these assumptions, a dicted, calculated as groups. On average, 93% of the weekly sample size of 88 participants per treat-F dosages in the azithromycin group and {[(FEV 1 % predicted at day 168-EV 1 % ment group provided 97.5% power to .. , "", 89% of the weekly dosages in the plapredicted at day 0) X lOOJ/FEV1% detect a significant difference between cebo group were used. predicted at day 0}, treatment groups (2-sided P=.05). Participants were screened until a maxi-was also compared between treatment Pulmonary Function mum of 185 participants were eligible for groups by using a .05 level 2-sided t test. Participants in the azithromycin group participation to account for attrition.
Between-group comparisons of propor-had an estimated 0. 7% (SD, 11.8% ) and the placebo group declined by 1.3% (SD, 9.0%) (mean difference, 5.0%; 95% CI, 1.9%-8.0%; P=.002).
Safety
Among the adverse events reported, only nausea, diarrhea, and wheezing were found to statistically differ between participants receiving azithromycin and those receiving placebo ( The original dosage was either modified, or stopped and restarted in 8 participants (4 in each group). The majority of serious adverse events were related to hospitalization for pulmonary exacerbations. Study drug was discontinued in 3 participants in the azithromycin group and 2 in the placebo group. In the azithromycin group, study drug was discontinued because of sore feet and bruising (n=1), sinusitis (n =1), or rash and ankle pain (n=1).
Microbiology
The microbiologic profiles of the participants in each treatment group were similar at screening (TABLE 3) . At day 168, 10% fewer participants in the azithromycin group had newly detected methicillin-susceptible Staphylococcus aureus (95% CI, -19% to -3%; P=.01). However, S aureus was not more likely to be eradicated in the azithromycin group; S aureus was eradicated from 18% of participants in the azithromycin group and 12% of participants in the placebo group (95% CI, -16% to 5%; P=.46). There was little difference between the 2 groups in the emergence or eradication of multidrugresistant strains of P aeruginosa or other potential pathogens, including nontu-berculous mycobacteria. P aeruginosa density decreased by 0.3 log colony forming units at day 168 in the azithromycin group and increased by 0.2 log colony forming units in the placebo group (mean difference, 0.5 log colony forming units; 95% CI, 0.4-0.6; P=.06).
Weight Gain
The rate of weight change was found to be higher among participants in the azithromycin group than in the placebo group . Participants in the azithromycin group gained an average 0.7 kg more than participants in the placebo group by day 168 (95% CI, 0.1-1.4 kg; P=.02).
Hospitalizations and Antibiotic Use
Participants in the azithromycin group had less risk of experiencing an exacerbation than participants in the placebo group (hazard ratio, 0.65; 95% CI, 0.44-0.95; P=.03) (FIGURE 3). There was a reduction in the number of participants hospitalized and the mean number of days of nonquinolone oral antibiotic use in the azithromycin group (TABLE 4) . Although not statistically significant, the azithromycin group experienced a 47% reduction in hospital days and a 39% reduction in the days of intravenous antibiotic use.
Quality of Life
Participants in the azithromycin group reported improvements in physical functioning on the CF Quality of Life Questionnaire in contrast with those in the placebo group (mean difference, 2.7; 95% CI, 0.1-5.3; P=.05). No significant differences were found between the groups in the scores for psychosocial functioning, body image factors, or total CF Quality of Life Questionnaire (TABLE 5) .
Inflammatory Markers
The mean (SD) elastase levels in the azithromycin and placebo groups were similar at baseline (1. 64 (74) 38 (44) 34 (39) 33 (38) 29 (33) 29 (33) 28 (32) 26 (30) 24 (28) 24 (28) 23 (26) 20 (23) 18 (21) 17 (20) 15 (17) 14 (16) 14 (16) 13 (15) 13 (15)
Placebo (n = 98)
80 (82) 36 (37) 48 (49) 36 (37) 16 (16) 25 (26) 31 (32) 31 (32) 36 (37) 36 (37) 24 (24) 8 (8) 19 (19) 25 (26) 4 (4) 9 (9) 15 (15) 7 (7) 15 (15) vs Placebo Participants* 27 Pulmonary function and nutritional status improved, pulmonary exacerbation rates decreased, and there was some evidence of improved quality of life. No unexpected adverse events were identified and the drug was generally well tolerated.
% Risk
The concomitant medications recombinant human dornase alfa inhalation solution and tobramycin solution for inhalation were widely used by participants during this study. The results suggested that participants had clinical benefits when azithromycin was added to other therapies proven to be effective in patients with CF. In addi- 
Microorganism

Pseudomonas aeruginosa Mucoid
Multidrug-resistant
Staphylococcus aureus
Methicillin-resistant S aureus
Nontuberculous mycobacteria
Burkholderia cepacia complex *Respiratory tract samples were available for baseline assessments in 87 participants (100%) in the azithromycin group and 97 (99%) of 98 participants in the placebo group. Respiratory tract samples were available at both baseline and day 168 for assessing newly detected pathogens from 84 (97%) participants in the azithromycin group and 92 (94%) participants in the placebo group. †These participants had acid-fast bacillus smear negative results but nontuberculous mycobacteria grew from the screening culture. Study drug was discontinued when the culture results were available. ‡At day 168, only 43 participants in the azithromycin group and 38 participants in the placebo group had sufficient sputum to process for nontuberculous mycobacteria. Kaplan-Meier method estimates of the proportion of patients remaining exacerbation-free during the active treatment phase of the study. P value derived from Cox proportional hazards regression model. tion, the impact of azithromycin was comparable with that reported in previous studies of these and other CF therapies. In this trial, the relative change in FEV 1 % predicted was 6.2% compared with the 5.6% and 11.0% treatment effects observed in studies of recombinant human dornase alfa and tobramycin solution for inhalation, respectively.
13,14
This The mechanism of action of azithromycin in patients with CF has not been elucidated. In vitro data suggest that azithromycin has bactericidal activity against P aeruginosa in stationary phase growth, 28 but azithromycin had minimal effect on bacterial density in this trial. Although azithromycin has activity against S aureus, this pathogen was not eradicated. The relative importance of Chlamydia pneumoniae and Mycoplasma pneumoniae in patients with CF is uncertain and was not evaluated in this trial, but the beneficial effect of azithromycin is unlikely to be mediated solely by impact on these organisms. Macrolide antibiotics show a modest degree of in vitro synergy with antipseudomonal antibiotics against gram-negative organisms from patients with CF. 29 An antiinflammatory mechanism of action has been suggested for macrolide antibiotics 30 but none of the clinical trials have shown statistically significant reductions in IL-8. The impact on neutrophil elastase noted in this trial was modest and of uncertain clinical significance. In the study by Wolter et al, 8 C-reactive protein declined in the azithromycin group but the C-reactive protein level was highly correlated with lung function as patients with normal C-reactive protein had better lung function. Macrolide antibiotics have been shown to decrease sputum viscosity 30,31 but this has not been systematically studied. We speculate that the increased wheezing reported by participants in the azithromycin group was because of increased mobilization of respiratory tract secretions. Future studies should assess changes in sputum rheology. Finally, a direct effect on the CF transmembrane conductance regulator has been postulated.
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The emergence of macrolideresistant nontuberculous mycobacteria is of concern when considering chronic azithromycin therapy for patients with CF. In a multicenter study conducted in Abbreviations: CI, confidence interval; IV, intravenous. *All parameters were measured from day 0 to day 168. 1000 patients with CF aged 10 years or older, the prevalence of nontuberculous mycobacteria was approximately 12%, although many patients did not fulfill American Thoracic Society criteria for active disease. 33, 34 Because of these concerns, potential participants in the azithromycin study were screened for nontuberculous mycobacteria. Physicians considering azithromycin therapy should assess patients with CF for nontuberculous mycobacteria before and every 6 months after initiating azithromycin. 23 The results of this trial suggest several avenues for future research. Only 19 participants aged 6 to12 years were enrolled and therefore further investigations are needed in younger patients with CF infected with P aeruginosa. This study did not assess the efficacy of azithromycin in patients infected with B cepacia complex or uninfected with P aeruginosa. Evaluation of the effects and safety of azithromycin beyond 24 weeks is needed as the decline in lung function after discontinuing azithromycin suggests that sustained benefit could be derived from more prolonged therapy. The emergence of resistance to macrolide antibiotics in oral flora, potentially S aureus, and nontuberculous mycobacteria should be monitored during longterm therapy.
Despite the remaining questions, azithromycin is medication that is currently available. Care providers of patients with CF should consider this therapy for patients with CF aged 6 years or older and chronically infected with P aeruginosa.
